학술논문

Core outcome sets for myocardial infarction in clinical trials of traditional Chinese medicine and Western medicine.
Document Type
Article
Source
Journal of Evidence-Based Medicine. Mar2024, Vol. 17 Issue 1, p86-94. 9p.
Subject
*CHINESE medicine
*MYOCARDIAL infarction
*CLINICAL trials
*CARDIOGENIC shock
*RANDOMIZED controlled trials
*CLINICAL trials monitoring
Language
ISSN
1756-5383
Abstract
Background: Clinical trials of traditional Chinese medicine (TCM) and Western medicine showed there was heterogeneity of outcome reporting in myocardial infarction (MI). Developing a core outcome set (COS) might improve the consistency of outcome reporting in future clinical trials. Methods: A list of outcomes was developed based on a systematic review of randomized controlled trials (RCTs) of MI and semistructured interviews with MI patients. Two rounds of Delphi survey for clinicians, researchers, journal editors, and methodologists were conducted. An online questionnaire sent to nurses. After an online consensus meeting, a COS for MI RCTs was developed. Results: After extracted data from clinical trials and discussed, 216 outcomes were included in round 1 of the Delphi survey. Seventy‐four participants completed round 1 of the Delphi survey. Sixty‐five participants completed round 2 of the Delphi survey. Twenty‐two nurses completed the online questionnaire. Fifteen participants attended the online consensus meeting, and 14 of them voted and determined the final COS. For all types of MI, it was recommended that left ventricular ejection fraction and quality of life be measured and reported. For acute MI, the participants in the consensus meeting recommended the following core outcomes: death from cardio‐cerebrovascular disease, cardiogenic shock, heart failure, troponin I, troponin T, creatine kinase isoenzyme, Killip class, target vessel revascularization, and emergency CABG. For previous MI, recurrent MI, recurrent angina pectoris, and heart failure readmission were recommended. Conclusions: The COS for MI in RCTs provides recommendations for clinical trials that seek to improve outcomes for patients with MI. [ABSTRACT FROM AUTHOR]